Somewhat Favorable Press Coverage Somewhat Unlikely to Impact National Research (NRCIA) Share Price
Media headlines about National Research (NASDAQ:NRCIA) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. National Research earned a news impact score of 0.16 on Accern’s scale. Accern also gave news headlines about the business services provider an impact score of 43.6139482134182 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s analysis:
- National Research Co. (NRCIA) Director Sells $19,216.80 in Stock (americanbankingnews.com)
- National Research (NRCIA) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
- Insider Selling: National Research Co. (NRCIA) Director Sells 2,383 Shares of Stock (americanbankingnews.com)
- Zacks: National Research Co. (NRCIA) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
National Research (NASDAQ:NRCIA) opened at $30.80 on Friday. The stock has a market capitalization of $763.49, a price-to-earnings ratio of 59.23 and a beta of 1.75. National Research has a fifty-two week low of $18.81 and a fifty-two week high of $41.99.
A number of research analysts recently issued reports on NRCIA shares. BidaskClub lowered National Research from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research upgraded National Research from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 10th.
In other National Research news, CEO Michael D. Hays sold 1,602,399 shares of National Research stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $39.03, for a total transaction of $62,541,632.97. Following the completion of the sale, the chief executive officer now directly owns 5,261,410 shares of the company’s stock, valued at approximately $205,352,832.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John N. Nunnelly sold 2,383 shares of National Research stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $31.74, for a total value of $75,636.42. Following the sale, the director now directly owns 31,842 shares of the company’s stock, valued at $1,010,665.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,866,804 shares of company stock valued at $164,234,313. 5.70% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-national-research-nrcia-share-price/1960617.html.
About National Research
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.